FDA allows Hookipa to begin human trial on prostate cancer drug, shares fall

Hookipa Pharma

25/07/2022 15:39

** Shares of Hookipa Pharma  HOOK.O  reverse from premarket
gains of ~15% to trade down 4% at $1.50 
    ** Biopharma co says U.S. Food and Drug Administration has
accepted its application to conduct human clinical trials of
HB-300   urn:newsml:reuters.com:*:nGNX9Grsn9 
    ** HB-300 is an arenaviral therapy, which HOOK is developing
as a treatment for advanced prostate cancer
    ** HOOK plans to begin early-stage studies for HB-300 by
early 2023
    ** Adds that U.S. health regulator also accepted HB-300's
Drug Master File (DMF), which is used to provide detailed and
information about a drug's manufacturing, packaging and storing
    ** As of last close, stock down ~33% YTD 

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))